Intervention of METTL3 expression (sh-M3), m6A catalytic activity (STM2457), or TGF-β signaling activation (LY2109761) could regulate cEndMT process in vitro and in vivo, subsequently influence FECD progression in vivo. This evidence concerns the gene TGFB1 and Fuchs endothelial corneal dystrophy.